New prostate cancer drug showing ‘remarkable’ results during clinical trial - The new drug, known as VIR-5500, uses a ...
A polygenic risk score was able to detect a high proportion of clinically significant prostate cancer. Cancer would not have been detected in 71.8% of patients with the use of PSA or MRI screening.
The methods of diagnosing and treating localised prostate cancer has changed significantly in the last two decades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results